Spark Wins First Ever Gene Therapy for Inherited Disease

Dec 20, 2017

The FDA has approved Spark Therapeutics’ treatment for a rare form of blindness — the first ever approved a gene therapy for an inherited disease.

Spark has yet to announced a price for the one-time treatment, but analysts predict that it will cost around $1 million

Spark’s drug, Luxturna, treats inherited retinal disease caused by defects in a gene known as RPE65 — a condition that affects between 1,000 and 2,000 people in the United States.

Read the Reuters coverage